Mankind Pharma to meet investors in Mumbai on June 1-2

Mankind Pharma Limited will participate in an investor conference in Mumbai on June 1, 2026, and June 2, 2026, organized by Bank of America. The company’s management and officials will engage with investors through group meetings and one-on-one sessions during these dates. The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company clarified that no unpublished price sensitive information (UPSI) shall be disclosed during the meeting. Discussions will be based on the general business outlook and information that is already available in the public domain. The schedule for the Investor Conference remains subject to change due to exigencies on either side.

Date	Name of Event	City	Meeting Type
June 1, 2026	Conference organized by Bank of America	Mumbai	Group Meeting
June 2, 2026	Meeting with various investors	Mumbai	One-on-One / Group Meeting

The intimation regarding participation in the Investor Conference has been uploaded on the official website of Mankind Pharma Limited. The announcement was signed by Hitesh Kumar Jain, Company Secretary & Compliance Officer of Mankind Pharma Limited.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.74%	+1.03%	-1.52%	+11.40%	+0.74%	+68.31%

Mankind Pharma witnessed a notable block trade on the National Stock Exchange (NSE), with approximately 1,30,780 shares changing hands in a single transaction. The deal was executed at a price of ₹2419.40 per share, aggregating to a total transaction value of ₹31.64 crores.

Block Trade Details

The following table summarises the key parameters of the block trade recorded on the NSE:

Parameter:	Details
Exchange:	NSE
Number of Shares:	~1,30,780
Trade Price:	₹2419.40 per share
Total Trade Value:	₹31.64 crores

Block trades of this scale are typically executed by large institutional investors or significant stakeholders and are carried out outside the regular order book to minimise market impact. The transaction in Mankind Pharma underscores continued institutional interest in the stock at the prevailing price level.